Fig. 4From: The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophreniaPerceptions of stigmatisation and impact of switch to PP3M on stigma. Footnote: a Stigma related to the diagnosis of schizophrenia. Stakeholders were asked ‘How stigmatised do you feel the patient is?’. b Impact of switch from PP1M to PP3M on stigma. Stakeholders were asked ‘To what extent do you think that PP3M impacts on the patient’s feeling of being stigmatised?’. PP3M, paliperidone palmitate 3-monthlyBack to article page